PHAT — Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 427
- Website: https://www.phathompharma.com
Latest SEC filings for PHAT
- 8-K — 2026-10-23
- 8-K — 2026-09-29
- 8-K — 2026-07-30
- 10-Q — 2026-07-30
- SCHEDULE 13G/A — 2026-07-20
- 8-K — 2026-06-23
- 8-K — 2026-05-21
- 8-K — 2026-04-30
- 10-Q — 2026-04-30
- ARS — 2026-04-07
Latest PHAT news
- — Phathom falls as FDA sued over refusal to accept ANDA for generic Voquezna (seekingalpha_market)
- — Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA (GlobeNewswire Inc.)
- — Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting (globenewswire.com)
- — Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD (globenewswire.com)
Educational tool only — not investment advice.